Knife-edge at Elan means no new CEO until bapineuzumab results are in
This article was originally published in Scrip
Executive Summary
Elan's board of directors has announced that instead of leaving the company in May this year as planned (scripintelligence.com, 3 June 2010), Kelly Martin will stay on as CEO until the upcoming completion of a North American Phase III trial of Alzheimer's drug bapineuzumab. The outcome of this trial, and the three other Phase III bapineuzumab trials, are critical to Elan's future direction.